ACLA Praises Gottlieb Confirmation as FDA Commissioner
Clinical Laboratory Community Commends New Commissioner For Both His Medical and Government Experience, Support for Scientific Innovation
(Washington, D.C.) – The Senate confirmation today of Scott Gottlieb, M.D. as Commissioner of the Food and Drug Administration (FDA), drew praise from the American Clinical Laboratory Association (ACLA), the nation’s leading organization representing clinical laboratories. Commending Dr. Gottlieb for his experience in both the clinical and public policy aspects of health care, the lab community applauded the announcement following today’s Senate confirmation.
“Dr. Gottlieb has expressed the need for the regulatory environment to promote innovation in laboratory testing, and we look forward to working with the new commissioner to advance diagnostic regulatory reform,” said Julie Khani, president of ACLA. “It is critical that any modernization of federal regulation of laboratory developed tests strikes the right balance between fostering innovation and ensuring continued patient access to these important testing services. ACLA welcomes Dr. Gottlieb’s expertise and leadership as FDA works with Congress and stakeholders on this issue.”
# # #
The ACLA is a not-for-profit association representing the nation’s leading national, regional and esoteric clinical laboratories on key issues of common concern, including federal and state government reimbursement and regulatory policies.
